Outcomes of Treatment and Predictors of Response to Sofosbuvir plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection.

CONCLUSIONS: Twelve weeks regimen of sofosbuvir plus simeprevir was considered to be safe and tolerable in treatment of HCV genotype 4; also it was associated with high SVR (97.6%).
PMID: 30569878 [PubMed - as supplied by publisher]

Source: Infectious Disorders Drug Targets - December 17, 2018 Category: Infectious Diseases Authors: Ahmed OA, Elsebaey MA, Fouad MHA, Elkadeem M, Badawi R, Khayyal A, Soliman S, Negm MS, Abd-Elsalam S Tags: Infect Disord Drug Targets Source Type: research